TRAWS PHARMA, INC.
TRAW evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TRAW—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TRAW
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company developing oral antiviral therapeutics, with lead candidates including ratutrelvir for COVID-19 and TRX-100 for other indications, currently facing significant financial uncertainty as a going concern.
Key risk: Going concern uncertainty
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 11 clinical trials for TRAWS PHARMA, INC..
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company developing oral antiviral therapeutics, with lead candidates including ratutrelvir for COVID-19 and TRX-100 for other indications, currently facing significant financial uncertainty as a going concern.
- Traws Pharma has completed Phase 1 trials for two oral candidates: 83-0060 (NCT06402136) and TRX-100 (NCT06757738) [catalyst].
- A Phase 2a study of ratutrelvir (NCT07157007) is currently recruiting [catalyst].
- As of June 30, 2026, the company reported cash & equivalents of $5.0M and a net loss of -$3.1M [sec].
- The company has not achieved profitability since inception and expects to continue incurring net losses [sec_mda · as of 2026-08-14].
- Management has expressed substantial doubt about the company's ability to continue as a going concern through the one-year period after the issuance of its financial statements [sec_mda · as of 2026-05-15].
What works
- Traws Pharma has advanced two oral candidates into clinical trials, with Phase 1 studies completed for 83-0060 and TRX-100 [catalyst].
- The company's Phase 2a study of ratutrelvir is actively recruiting, indicating ongoing clinical development [catalyst].
- Potential additional proceeds of up to $30.0 million from common warrants, if exercised, could provide future funding [sec_mda · as of 2026-08-14].
What to weigh
- The company has not achieved profitability since inception and expects to continue incurring net losses for the foreseeable future [sec_mda · as of 2026-08-14].
- Based on current projections, the company does not have sufficient cash to support operations for more than one year, raising substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-05-15].
- The company faces significant need for additional financing to fund future clinical trials and operations, and there is no assurance that milestone-based or common warrants will be exercised [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
The company has not achieved profitability and expects continued net losses.
“We have not achieved profitability since our inception and we expect to continue to incur net losses for the foreseeable future.”
SEC MD&A · August 14, 2026
Potential additional proceeds from common warrants could be $30.0 million if fully exercised.
“common warrants, subject to shareholder approval, with a three-year term to purchase shares of our common stock, providing potential additional gross proceeds of $30.0 million if fully exercised.”
SEC MD&A · August 14, 2026
Phase 2a study of ratutrelvir is recruiting.
“Phase 2 Start: A Multicenter, Open-Label, Randomized Phase 2a Study to Evaluate Safety and Efficacy of Ratutrelvir - NCT: NCT07157007. Status: Recruiting.”
Catalysts
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern due to insufficient cash for more than one year [sec_mda · as of 2026-05-15].
- Need for additional financing — Company requires additional capital for clinical trials and operations; no assurance of obtaining funds on acceptable terms [sec_mda · as of 2026-08-14].
- Warrant exercise uncertainty — Milestone-based and common warrants may not be exercised, limiting potential funding [sec_mda · as of 2026-08-14].
- Clinical trial risks — Phase 2a trial of ratutrelvir is recruiting; outcomes and regulatory approvals are uncertain [catalyst].
What to watch
- Progress and data from the Phase 2a study of ratutrelvir (NCT07157007) [catalyst].
- Ability to secure additional financing or exercise of warrants to extend cash runway [sec_mda · as of 2026-08-14].
- Any updates on the company's going concern status and financial projections [sec_mda · as of 2026-05-15].
Sources: Catalysts · SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run TRAWS PHARMA, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available TRAWS PHARMA, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
2.5 months
OCF -$8M · Net income -$3M
Lead: Phase 3
4 candidates
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is the AI investment thesis for TRAWS PHARMA, INC.?
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company developing oral antiviral therapeutics, with lead candidates including ratutrelvir for COVID-19 and TRX-100 for other indications, currently facing significant financial uncertainty as a going concern.
What is TRAWS PHARMA, INC.'s lead drug candidate?
TRAWS PHARMA, INC.'s most advanced tracked candidate is narazaciclib (Phase 1) for solid tumors and hematological malignancies.
Who is the CEO of TRAWS PHARMA, INC.?
Dr. Iain D. Dukes DPHIL, M.A., Ph.D. is the chief executive officer of TRAWS PHARMA, INC. (TRAW).
Where is TRAWS PHARMA, INC. headquartered?
TRAWS PHARMA, INC. (TRAW) is headquartered in Newtown, PA, United States.
What therapeutic areas does TRAWS PHARMA, INC. focus on?
TRAWS PHARMA, INC. develops therapies across Oncology, Infectious Disease, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.